Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

Su, Ya-Na; Zhao, Ding-Yun; Li, Yonghong; Yu, Tianqi; Sun, Huan; Wu, Xinyu; Zhou, Xiaoqin; Li, Jing

doi:10.1111/iwj.13318

Cited by 23 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional comparative effectiveness studies with different materials and bigger groups of chronic wounds of various origin would be beneficial to specify more accurate indications and timing for Amnioderm® application. As part of the use of AM or AM + chorion in patients with DFUs, two meta-analyses were also published that summarized efficacy and safety (Su et al, 2020 ). In Huang et al, a total of nine randomized controlled trials (RCTs) with a total of 541 patients are included.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Freeze-Dried Human Amniotic Membrane Allograft for the Treatment of Chronic Wounds: Results of a Multicentre Observational Study

Schmiedova

Ozanova

Stastna

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

An inability of the human body to heal acute wounds under certain conditions results in the formation of chronic ulcers. Chronic wounds not only cause significant pain and discomfort for patients but also serve as an entry for microorganisms into the human body, which can result in serious life-threatening problems and become a significant burden for the patients and society. The current work present results of a multicentre prospective observational study demonstrating the use of a lyophilized amniotic membrane (AM) in the treatment of chronic wounds (various etiologies). Lyophilized AM produced under the commercial brand Amnioderm® was used as an allograft material for therapy of chronic wounds, in addition to chronic ulcer standard-of-care (SoC) protocols. The duration of wounds considered for the application of AM ranged between 2 months and 11 years. In total, 16 patients were enrolled to the study, of which eight were completely healed, six demonstrated a significantly reduced ulcer size, and two did not respond to the AM therapy. The current study unambiguously demonstrates an effective alternative to the standard of chronic wound care and confirms a significant effect of the AM application for chronic wound management as a new SoC.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Freeze-Dried Human Amniotic Membrane Allograft for the Treatment of Chronic Wounds: Results of a Multicentre Observational Study

Schmiedova

Ozanova

Stastna

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…According to a systematic review and meta-analysis study, the safety and efficiency of AAM have been confirmed in the treatment of split-thickness skin graft donor sites [57]. For chronic diabetic foot ulcers, a shorter time to complete healing and a higher proportion of complete healing were observed in the AAM group when compared with the standard wound care group [58].…”

Section: Acellular Amniotic Membrane (Aam)mentioning

confidence: 98%

Membranous Extracellular Matrix-Based Scaffolds for Skin Wound Healing

Huang

Xie

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

Membranous extracellular matrix (ECM)-based scaffolds are one of the most promising biomaterials for skin wound healing, some of which, such as acellular dermal matrix, small intestinal submucosa, and amniotic membrane, have been clinically applied to treat chronic wounds with acceptable outcomes. Nevertheless, the wide clinical applications are always hindered by the poor mechanical properties, the uncontrollable degradation, and other factors after implantation. To highlight the feasible strategies to overcome the limitations, in this review, we first outline the current clinical use of traditional membranous ECM scaffolds for skin wound healing and briefly introduce the possible repair mechanisms; then, we discuss their potential limitations and further summarize recent advances in the scaffold modification and fabrication technologies that have been applied to engineer new ECM-based membranes. With the development of scaffold modification approaches, nanotechnology and material manufacturing techniques, various types of advanced ECM-based membranes have been reported in the literature. Importantly, they possess much better properties for skin wound healing, and would become promising candidates for future clinical translation.

show abstract

“…70 A recent meta-analysis including 465 participants showed that there was a 2-fold higher probability of complete wound healing at 12 weeks for patients who received human amniotic membrane plus standard of care in comparison with those receiving only standard of care and also a significantly shorter time to healing (about 30 days). 71 Moreover, some RCTs showed higher probability of wound healing for patients receiving human amniotic membrane products when compared with bioengineered skin substitutes. 72,73 However, 2 retrospective analyses of real world data did not confirm these findings and instead showed superiority of bioengineered skin substitutes.…”

Section: Adjunct Therapiesmentioning

confidence: 99%

Nonpharmacological Management of Diabetic Foot Ulcers: An Update

Eleftheriadou

Samakidou

Tentolouris

et al. 2020

The International Journal of Lower Extremity Wounds

View full text Add to dashboard Cite

Diabetic foot ulcers (DFUs) are a common and serious complication of diabetes mellitus that is associated with increased morbidity and mortality, as well as substantial economic burden for the health care system. The standard of care for DFUs includes pressure off-loading, sharp debridement, and wound moisture balance, along with infection control and management of peripheral arterial disease. A variety of advanced modalities that target distinct pathophysiological aspects of impaired wound healing in diabetes are being studied as possible adjunct therapies for difficult to heal ulcers. These modalities include growth factors, stem cells, cultured fibroblasts and keratinocytes, bioengineered skin substitutes, acellular bioproducts, human amniotic membranes, oxygen therapy, negative pressure wound therapy, and energy therapies. Additionally, the use of advanced biomaterials and gene delivery systems is being investigated as a method of effective delivery of substances to the wound bed. In the present narrative review, we outline the latest advances in the nonpharmacological management of DFUs and summarize the efficacy of various standard and advanced treatment modalities.

show abstract

Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

Cited by 23 publications

References 25 publications

Case Report: Freeze-Dried Human Amniotic Membrane Allograft for the Treatment of Chronic Wounds: Results of a Multicentre Observational Study

Case Report: Freeze-Dried Human Amniotic Membrane Allograft for the Treatment of Chronic Wounds: Results of a Multicentre Observational Study

Membranous Extracellular Matrix-Based Scaffolds for Skin Wound Healing

Nonpharmacological Management of Diabetic Foot Ulcers: An Update

Contact Info

Product

Resources

About